In lung adenocarcinoma, the expression of RUNX2 correlated with a poor hazard ratio, suggesting that RUNX2 plays a clinical role as an independent risk factor for poor survival in lung cancer [59]. This evidence concerns the gene RUNX2 and lung adenocarcinoma.